THE CAMPAIGN FOR SUSTAINABLE RX PRICING — Lobbying Disclosure | Poliscope

THE CAMPAIGN FOR SUSTAINABLE RX PRICING

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2016–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	3	1
2025	—	4	1
2024	—	4	1
2023	—	4	1
2022	—	4	1
2021	—	4	1
2020	—	5	1
2019	—	5	2
2018	—	8	2
2017	—	8	2
2016	—	8	2

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
MEHLMAN CONSULTING, INC.	—	45
ML STRATEGIES, LLC	—	12

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	53
SENATE	53
Health & Human Services, Dept of (HHS)	46
Centers For Medicare and Medicaid Services (CMS)	20
Food & Drug Administration (FDA)	11
Patent & Trademark Office (PTO)	8
White House Office	8
Executive Office of the President (EOP)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Pharmacy	Pharmacy	56
Medicare/Medicaid	Medicare/Medicaid	56
Health Issues	Health Issues	33
Copyright/Patent/Trademark	Copyright/Patent/Trademark	24
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	3
Trade (domestic/foreign)	Trade (domestic/foreign)	3
Budget/Appropriations	Budget/Appropriations	2

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 1262119th Congress

Mikaela Naylon Give Kids a Chance Act

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Prescription drug pricing issues. H.R. 1843/S. 1032 - Increasing Transparency in Generic Drug Applications Act. S. 1954/H.R. 5526 - Biosimilar Red Tape Elimination Act; S. 1095 - Stop Stalling Act S. 2630 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act H.R.1262 - Mikaela Naylon Give Kids a Chance Act. S. 3014 - Ensuring Timely Access to Generics Act of 2025 S. 1414 - Expedited Access to Biosimilars Act

Client expense: — · Firm income: $90,000

Matched citations: H.R.1262

H.R. 1843119th Congress

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Prescription drug pricing issues. H.R. 1843/S. 1032 - Increasing Transparency in Generic Drug Applications Act. S. 1954/H.R. 5526 - Biosimilar Red Tape Elimination Act; S. 1095 - Stop Stalling Act S. 2630 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act H.R.1262 - Mikaela Naylon Give Kids a Chance Act. S. 3014 - Ensuring Timely Access to Generics Act of 2025 S. 1414 - Expedited Access to Biosimilars Act

Client expense: — · Firm income: $90,000

Matched citations: H.R. 1843

H.R. 3010119th Congress

No Handouts for Drug Advertisements Act

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 1785/H.R. 3010 - The No Handouts for Drug Advertisements Act.

Client expense: — · Firm income: $90,000

Matched citations: H.R. 3010

H.R. 3152119th Congress

Patent Eligibility Restoration Act of 2025

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S. 1097/H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025. S. 43/H.R. 6485 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - Eliminating Thickets to Increase Competition (ETHIC) Act. H.R. 3160/S. 1533 - The Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act.

Client expense: — · Firm income: $90,000

Matched citations: H.R. 3152

Show 21 more cited filings

H.R. 3160119th Congress

PREVAIL Act

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S. 1097/H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025. S. 43/H.R. 6485 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - Eliminating Thickets to Increase Competition (ETHIC) Act. H.R. 3160/S. 1533 - The Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act.

Client expense: — · Firm income: $90,000

Matched citations: H.R. 3160

H.R. 3269119th Congress

ETHIC Act

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S. 1097/H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025. S. 43/H.R. 6485 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - Eliminating Thickets to Increase Competition (ETHIC) Act. H.R. 3160/S. 1533 - The Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act.

Client expense: — · Firm income: $90,000

Matched citations: H.R. 3269

H.R. 3789119th Congress

DTC Act of 2025

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Prescription drug pricing issues. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S. 229 - The Drug-price Transparency for Consumers (DTC) Act.

Client expense: — · Firm income: $90,000

Matched citations: H.R. 3789

H.R. 4570119th Congress

Interagency Patent Coordination and Improvement Act of 2025

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S. 1097/H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025. S. 43/H.R. 6485 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - Eliminating Thickets to Increase Competition (ETHIC) Act. H.R. 3160/S. 1533 - The Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act.

Client expense: — · Firm income: $90,000

Matched citations: H.R. 4570

H.R. 5526119th Congress

Biosimilar Red Tape Elimination Act

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Prescription drug pricing issues. H.R. 1843/S. 1032 - Increasing Transparency in Generic Drug Applications Act. S. 1954/H.R. 5526 - Biosimilar Red Tape Elimination Act; S. 1095 - Stop Stalling Act S. 2630 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act H.R.1262 - Mikaela Naylon Give Kids a Chance Act. S. 3014 - Ensuring Timely Access to Generics Act of 2025 S. 1414 - Expedited Access to Biosimilars Act

Client expense: — · Firm income: $90,000

Matched citations: H.R. 5526

H.R. 6485119th Congress

Skinny Labels, Big Savings Act

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S. 1097/H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025. S. 43/H.R. 6485 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - Eliminating Thickets to Increase Competition (ETHIC) Act. H.R. 3160/S. 1533 - The Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act.

Client expense: — · Firm income: $90,000

Matched citations: H.R. 6485

S. 1032119th Congress

Major Richard Star Act

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Prescription drug pricing issues. H.R. 1843/S. 1032 - Increasing Transparency in Generic Drug Applications Act. S. 1954/H.R. 5526 - Biosimilar Red Tape Elimination Act; S. 1095 - Stop Stalling Act S. 2630 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act H.R.1262 - Mikaela Naylon Give Kids a Chance Act. S. 3014 - Ensuring Timely Access to Generics Act of 2025 S. 1414 - Expedited Access to Biosimilars Act

Client expense: — · Firm income: $90,000

Matched citations: S. 1032

S. 1040119th Congress

Drug Competition Enhancement Act

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S. 1097/H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025. S. 43/H.R. 6485 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - Eliminating Thickets to Increase Competition (ETHIC) Act. H.R. 3160/S. 1533 - The Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act.

Client expense: — · Firm income: $90,000

Matched citations: S.1040

S. 1041119th Congress

Affordable Prescriptions for Patients Act

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S. 1097/H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025. S. 43/H.R. 6485 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - Eliminating Thickets to Increase Competition (ETHIC) Act. H.R. 3160/S. 1533 - The Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act.

Client expense: — · Firm income: $90,000

Matched citations: S.1041

S. 1095119th Congress

Stop STALLING Act

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Prescription drug pricing issues. H.R. 1843/S. 1032 - Increasing Transparency in Generic Drug Applications Act. S. 1954/H.R. 5526 - Biosimilar Red Tape Elimination Act; S. 1095 - Stop Stalling Act S. 2630 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act H.R.1262 - Mikaela Naylon Give Kids a Chance Act. S. 3014 - Ensuring Timely Access to Generics Act of 2025 S. 1414 - Expedited Access to Biosimilars Act

Client expense: — · Firm income: $90,000

Matched citations: S. 1095

S. 1096119th Congress

Preserve Access to Affordable Generics and Biosimilars Act

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S. 1097/H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025. S. 43/H.R. 6485 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - Eliminating Thickets to Increase Competition (ETHIC) Act. H.R. 3160/S. 1533 - The Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act.

Client expense: — · Firm income: $90,000

Matched citations: S.1096

S. 1097119th Congress

Interagency Patent Coordination and Improvement Act of 2025

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S. 1097/H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025. S. 43/H.R. 6485 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - Eliminating Thickets to Increase Competition (ETHIC) Act. H.R. 3160/S. 1533 - The Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act.

Client expense: — · Firm income: $90,000

Matched citations: S. 1097

S. 1414119th Congress

Expedited Access to Biosimilars Act

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Prescription drug pricing issues. H.R. 1843/S. 1032 - Increasing Transparency in Generic Drug Applications Act. S. 1954/H.R. 5526 - Biosimilar Red Tape Elimination Act; S. 1095 - Stop Stalling Act S. 2630 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act H.R.1262 - Mikaela Naylon Give Kids a Chance Act. S. 3014 - Ensuring Timely Access to Generics Act of 2025 S. 1414 - Expedited Access to Biosimilars Act

Client expense: — · Firm income: $90,000

Matched citations: S. 1414

S. 1533119th Congress

A bill to amend title 38, United States Code, to make permanent and codify the pilot program for use of contract physicians for disability examinations, and for other purposes.

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S. 1097/H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025. S. 43/H.R. 6485 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - Eliminating Thickets to Increase Competition (ETHIC) Act. H.R. 3160/S. 1533 - The Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act.

Client expense: — · Firm income: $90,000

Matched citations: S. 1533

S. 1546119th Congress

Patent Eligibility Restoration Act of 2025

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S. 1097/H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025. S. 43/H.R. 6485 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - Eliminating Thickets to Increase Competition (ETHIC) Act. H.R. 3160/S. 1533 - The Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act.

Client expense: — · Firm income: $90,000

Matched citations: S. 1546

S. 1785119th Congress

No Handouts for Drug Advertisements Act

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 1785/H.R. 3010 - The No Handouts for Drug Advertisements Act.

Client expense: — · Firm income: $90,000

Matched citations: S. 1785

S. 1954119th Congress

Biosimilar Red Tape Elimination Act

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Prescription drug pricing issues. H.R. 1843/S. 1032 - Increasing Transparency in Generic Drug Applications Act. S. 1954/H.R. 5526 - Biosimilar Red Tape Elimination Act; S. 1095 - Stop Stalling Act S. 2630 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act H.R.1262 - Mikaela Naylon Give Kids a Chance Act. S. 3014 - Ensuring Timely Access to Generics Act of 2025 S. 1414 - Expedited Access to Biosimilars Act

Client expense: — · Firm income: $90,000

Matched citations: S. 1954

S. 2276119th Congress

ETHIC Act

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S. 1097/H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025. S. 43/H.R. 6485 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - Eliminating Thickets to Increase Competition (ETHIC) Act. H.R. 3160/S. 1533 - The Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act.

Client expense: — · Firm income: $90,000

Matched citations: S. 2276

S. 229119th Congress

DTC Act of 2025

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Prescription drug pricing issues. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S. 229 - The Drug-price Transparency for Consumers (DTC) Act.

Client expense: — · Firm income: $90,000

Matched citations: S. 229

S. 2630119th Congress

Saving NSF’s Workforce Act

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Prescription drug pricing issues. H.R. 1843/S. 1032 - Increasing Transparency in Generic Drug Applications Act. S. 1954/H.R. 5526 - Biosimilar Red Tape Elimination Act; S. 1095 - Stop Stalling Act S. 2630 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act H.R.1262 - Mikaela Naylon Give Kids a Chance Act. S. 3014 - Ensuring Timely Access to Generics Act of 2025 S. 1414 - Expedited Access to Biosimilars Act

Client expense: — · Firm income: $90,000

Matched citations: S. 2630

S. 3014119th Congress

Ensuring Timely Access to Generics Act of 2025

2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Prescription drug pricing issues. H.R. 1843/S. 1032 - Increasing Transparency in Generic Drug Applications Act. S. 1954/H.R. 5526 - Biosimilar Red Tape Elimination Act; S. 1095 - Stop Stalling Act S. 2630 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act H.R.1262 - Mikaela Naylon Give Kids a Chance Act. S. 3014 - Ensuring Timely Access to Generics Act of 2025 S. 1414 - Expedited Access to Biosimilars Act

Client expense: — · Firm income: $90,000

Matched citations: S. 3014

Source: Senate LDA